TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28270022

Group type: EXPERIMENTAL
Intervention: AR-42, an oral pan-HDAC inhibitor, 40 mg dosed three times weekly for three weeks of a 28-day cycle
Number of subjects: 0
Study: 28270092

Group type: EXPERIMENTAL
Intervention: T-Track® CMV
Number of subjects: 124

Group type: COMPARATOR
Intervention: QuantiFERON®-CMV
Number of subjects: 124

Group type: COMPARATOR
Intervention: iTAg™ MHC Tetramer
Number of subjects: 124

Group type: COMPARATOR
Intervention: iTAg™ MHC Tetramers
Number of subjects: 124
Study: 28270121

Group type: EXPERIMENTAL
Intervention: Stereotactic prostate adaptive radiotherapy utilizing Kilovoltage Intrafraction Monitoring (KIM)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional treatment (not explicitly mentioned in the abstract)
Number of subjects: 48
Study: 28270136

Group type: EXPERIMENTAL
Intervention: Patients referred from different hospitals
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Increased travel distance to the regional centre
Number of subjects: 394

Group type: COMPARATOR
Intervention: Patients from each hospital
Number of subjects: 394

Group type: COMPARATOR
Intervention: Annual operation rate for PC
Number of subjects: 394

Group type: COMPARATOR
Intervention: Median travel distance for patients from the five hospitals
Number of subjects: 394
Study: 28270162

Group type: EXPERIMENTAL
Intervention: Weekly doses of paclitaxel (50 mg/m) and 5-fluorouracil (5-FU) with concurrent radiation therapy (50.4 Gy/28 Fx or 61.2 Gy/34 Fx) followed by 2 cycles of consolidation chemotherapy
Number of subjects: 53
Study: 28270167

Group type: EXPERIMENTAL
Intervention: Analgesia/Sedation (A/S) practices
Number of subjects: 6680

Group type: EXPERIMENTAL
Intervention: Pain Assessment (PA) practices
Number of subjects: 6680
Study: 28270212

Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150 μg every other week combined with hCG twice-weekly for 52 weeks
Number of subjects: 18
Study: 28270435

Group type: EXPERIMENTAL
Intervention: Multikinase inhibitors initiated at study entry (cohort 1)
Number of subjects: 700

Group type: COMPARATOR
Intervention: No multikinase inhibitors initiated at study entry (cohort 2)
Number of subjects: 700
Study: 28270536

Group type: EXPERIMENTAL
Intervention: Greater tract-level social disorder
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Greater tract-level social disadvantage
Number of subjects: 737
Study: 28270757

Group type: EXPERIMENTAL
Intervention: Meditative Movement practices (12 hours of training)
Number of subjects: 14
Study: 28270916

Group type: EXPERIMENTAL
Intervention: Active knowledge translation intervention (audit and feedback, patient- and provider-directed educational tools delivered at a comprehensive in-person medical detailing visit)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 55
Study: 28270924

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28271017

Group type: EXPERIMENTAL
Intervention: Practice facilitation by practice facilitators (PFs)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Enablers of implementation
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall implementation success
Number of subjects: 84
Study: 28271639

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) using CyberKnife technology, 36.25 Gy in five fractions
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) using CyberKnife technology
Number of subjects: 45
Study: 28273222

Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 0
Study: 28273780

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs) - 33% oral, 66% injectable
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Parental involvement in adherence
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral DMTs
Number of subjects: 66
Study: 28274211

Group type: EXPERIMENTAL
Intervention: Single dose ablative radiation treatment (20 Gy to the tumor and 15 Gy to the tumor bed)
Number of subjects: 25
Study: 28274221

Group type: EXPERIMENTAL
Intervention: Community Health Assessment Program through EMS (CHAP-EMS)
Number of subjects: 79
Study: 28274235

Group type: EXPERIMENTAL
Intervention: Pre-epiglottic baton plate (PEBP) treatment
Number of subjects: 49
Study: 28274254

Group type: EXPERIMENTAL
Intervention: Two different dosing regimens for the maintenance of remission in ulcerative colitis (CODA study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orally administered treatment (ZICE study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenously administered treatment (ZICE study)
Number of subjects: 0
Study: 28274904

Group type: EXPERIMENTAL
Intervention: Combination HIV prevention package including HIV testing and counseling, voluntary medical circumcision, condoms for males, PrEP, conditional cash transfer, contraceptives for females, and referrals for HIV care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile health teams delivering the combination HIV prevention package.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age- and gender-specific combination HIV prevention interventions.
Number of subjects: 0
Study: 28274957

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 28274963

Group type: EXPERIMENTAL
Intervention: Multimodal MRI (structural MRI, functional MRI, diffusion tensor imaging) in aMCI group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Multimodal MRI (structural MRI, functional MRI, diffusion tensor imaging) in VaMCI group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation in aMCI group
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation in VaMCI group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Neuropsychological evaluation in NC group
Number of subjects: 240
Study: 28275099

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other Diet Quality Indexes
Number of subjects: 0
Study: 28275101

Group type: EXPERIMENTAL
Intervention: Higher maternal dietary protein intake
Number of subjects: 0
Study: 28275119

Group type: EXPERIMENTAL
Intervention: Pilaralisib (200 mg QD) in combination with paclitaxel and carboplatin
Number of subjects: 58

Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin
Number of subjects: 58
Study: 28275165

Group type: EXPERIMENTAL
Intervention: SAFEHEART risk equation
Number of subjects: 2404

Group type: COMPARATOR
Intervention: modified Framingham risk equation
Number of subjects: 2404

Group type: COMPARATOR
Intervention: American College of Cardiology/American Heart Association ASCVD Pooled Cohort Risk Equations
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Fatal incident ASCVD
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Nonfatal incident ASCVD
Number of subjects: 2404
Study: 28275176

Group type: EXPERIMENTAL
Intervention: saHBEC co-cultured with moDC
Number of subjects: 2

Group type: COMPARATOR
Intervention: cHBEC co-cultured with moDC
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: saHBEC stimulated with particulate matter
Number of subjects: 2

Group type: COMPARATOR
Intervention: cHBEC stimulated with particulate matter
Number of subjects: 2
Study: 28275197

Group type: EXPERIMENTAL
Intervention: BOLD signal temporal delay
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DSC-MRI parameters (Tmax, mean transit time, cerebral blood flow, cerebral blood volume)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Receiver-operator characteristic (ROC) analysis for severe hypoperfusion (Tmax >6 seconds)
Number of subjects: 30
Study: 28275886

Group type: EXPERIMENTAL
Intervention: mRECIST (modified RECIST 1.1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: RANO-HGG (RANO high-grade glioma)
Number of subjects: 36

Group type: COMPARATOR
Intervention: RECIST 1.1
Number of subjects: 36

Group type: COMPARATOR
Intervention: RANO-BM (RANO brain metastasis)
Number of subjects: 36
Study: 28275958

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg once daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Other DPP-4 inhibitors (linagliptin, saxagliptin, sitagliptin, vildagliptin) at their recommended daily doses
Number of subjects: 8
Study: 28275966

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) program delivered by breast cancer survivors (compañeras)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) program
Number of subjects: 80
Study: 28276900

Group type: EXPERIMENTAL
Intervention: Dietary soluble fibres developed by enzymatic synthesis with α-(1,2) branching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: α-(1,3)-linked and α-(1,6)-linked glucose oligomers
Number of subjects: 0
Study: 28277107

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 509
Study: 28277349

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy during pregnancy (various adherence levels and durations)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Cesarean delivery (elective and nonelective)
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: No antiretroviral therapy during pregnancy
Number of subjects: 1857

Group type: EXPERIMENTAL
Intervention: Viral load greater than 1,000 copies/mL
Number of subjects: 1857
Study: 28277363

Group type: EXPERIMENTAL
Intervention: Iterative technique
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standardized technique
Number of subjects: 28
Study: 28277702

Group type: EXPERIMENTAL
Intervention: 8-session group-based weekly comprehensive trauma management and smoking cessation treatment focusing on skills to alleviate PTSD symptoms.
Number of subjects: 90
Study: 28277735

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa symptoms
Number of subjects: 0
Study: 28278476

Group type: EXPERIMENTAL
Intervention: Intracortical Brain-Computer Interfaces (BCIs)
Number of subjects: 0
Study: 28279376

Group type: EXPERIMENTAL
Intervention: Imaging use in treatment decision-making for valvular heart disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trial data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge gaps in imaging use
Number of subjects: 0
Study: 28279641

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) at 4 mA
Number of subjects: 18
Study: 28279891

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 50-200mg/day
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) ≥50mg/day
Number of subjects: 1160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1160

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 1160
Study: 28280103

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel treatment; genetic polymorphisms assessed by MassARRAY method.
Number of subjects: 249
Study: 28280134

Group type: EXPERIMENTAL
Intervention: Comprehensive genomic evaluation including whole exome sequencing, deletion and CNV analyses
Number of subjects: 61

Group type: COMPARATOR
Intervention: Healthy mutation-negative individuals (control group)
Number of subjects: 61
Study: 28280887

Group type: EXPERIMENTAL
Intervention: Brivaracetam 2.0 mg/kg bid (maximum 100 mg bid for body weight >50 kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brivaracetam co-administered with phenobarbital
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brivaracetam co-administered with carbamazepine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brivaracetam co-administered with valproate
Number of subjects: 96
Study: 28280901

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (screening plus training and support in intensive multifactorial treatment)
Number of subjects: 21513

Group type: COMPARATOR
Intervention: Routine care group (screening plus routine care of individuals with screen-detected diabetes)
Number of subjects: 21513
Study: 28280971

Group type: EXPERIMENTAL
Intervention: LY3022859 infused IV at 1.25 mg/kg over 1 h every 2 weeks (cohort 1A)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LY3022859 infused IV at flat doses of 12.5 mg (cohort 1B)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LY3022859 infused IV at flat doses of 25 mg (cohort 2)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: LY3022859 at 25 mg dose level after fifth infusion
Number of subjects: 14
Study: 28281183

Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg/daily) plus high dose carboplatin (AUC 6) and paclitaxel (200 mg/m2) in Cohort A
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg/daily) plus standard dose carboplatin (AUC 5) and paclitaxel (175 mg/m2) in Cohort B
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall response rate for both cohorts
Number of subjects: 14
Study: 28281228

Group type: EXPERIMENTAL
Intervention: RISQ-PATH score (≥10 points)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Baseline QTc-interval
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Follow-up QTc-interval
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Overall QTc-interval change
Number of subjects: 178
Study: 28281731

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (ASA + clopidogrel)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 608
Study: 28281907

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (HAB; Twinrix™, GSK Vaccines, Belgium)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Challenge dose of monovalent hepatitis A vaccine (N=2) or hepatitis B vaccine (N=2)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Mathematical modeling based on immunogenicity results
Number of subjects: 307
Study: 28282271

Group type: EXPERIMENTAL
Intervention: Lambda/RBV/DCV for 12 weeks, followed by Lambda/RBV for an additional 12 weeks in cohort A; response-guided therapy in cohort B.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lambda/RBV/DCV
Number of subjects: 300
Study: 28282585

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.7 g/day of EPA+DHA)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1.8 g/day of EPA+DHA)
Number of subjects: 191
Study: 28282612

Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily for 2 years
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nilotinib
Number of subjects: 38
Study: 28282878

Group type: EXPERIMENTAL
Intervention: Active Neighborhood Checklist (the Checklist)
Number of subjects: 82
Study: 28283497

Group type: EXPERIMENTAL
Intervention: Limit of detection (LOD, hs-cTnI<2 ng/L)
Number of subjects: 2828

Group type: EXPERIMENTAL
Intervention: Single cutoff (hs-cTnI<5 ng/L)
Number of subjects: 2828

Group type: EXPERIMENTAL
Intervention: 1-hour algorithm (hs-cTnI<5 ng/L and 1-hour change<2 ng/L)
Number of subjects: 2828

Group type: EXPERIMENTAL
Intervention: 0/1-hour algorithm (recommended in the European Society of Cardiology guideline)
Number of subjects: 2828
Study: 28283511

Group type: EXPERIMENTAL
Intervention: Wirion Embolic Protection System
Number of subjects: 120

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 120
Study: 28283596

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 400 U
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 600 U
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 600-800 U
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (all doses)
Number of subjects: 155
Study: 28283605

Group type: EXPERIMENTAL
Intervention: Increased oxygen extraction fraction (OEF)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Normal oxygen extraction fraction (OEF)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Increased OEF (per hemisphere)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Censored patients due to revascularization surgery
Number of subjects: 49
Study: 28283699

Group type: EXPERIMENTAL
Intervention: Open lung strategy with PEEP 15 cmH2O
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-dose end-expiratory CT scans at PEEP 5 and 15 cmH2O
Number of subjects: 33
Study: 28283746

Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 (ES3) valve
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Baseline first degree atrioventricular block (AVB)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Preprocedural complete right bundle branch block (RBBB)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: New-onset left bundle branch block after TAVI
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Baseline first degree AVB
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Preprocedural complete RBBB
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Oversizing and implantation depth
Number of subjects: 335
Study: 28283904

Group type: EXPERIMENTAL
Intervention: ePrognosis score 0-2
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: ePrognosis score 3-6
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: ePrognosis score 7-10
Number of subjects: 971
Study: 28284475

Group type: EXPERIMENTAL
Intervention: Acute bronchiolitis
Number of subjects: 531

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Boys at 2 years of age
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Girls at 2 years of age
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Infants at the time of acute bronchiolitis
Number of subjects: 531

Group type: COMPARATOR
Intervention: Reference group at 2 years of age
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Girls at 2 years of age vs Boys
Number of subjects: 531
Study: 28284536

Group type: EXPERIMENTAL
Intervention: Dactylis glomerate pollen challenge (4-hour duration, two challenges with 21 days interval)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dactylis glomerate pollen challenge (4-hour duration, second challenge)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Dactylis glomerate pollen challenge (4-hour duration, repetitive challenge)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Total nasal symptom score
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nasal nitric oxide levels
Number of subjects: 34
Study: 28284916

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell (MSC) infusion (1.5-3×10^6 cells)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (standard immunosuppression without MSC infusion)
Number of subjects: 10
Study: 28284978

Group type: EXPERIMENTAL
Intervention: 50 IU/kg of recombinant human C1 esterase inhibitor (rhC1INH)
Number of subjects: 127
Study: 28285070

Group type: EXPERIMENTAL
Intervention: Treatment-level FRAX score calculation with bone mineral density
Number of subjects: 6096

Group type: EXPERIMENTAL
Intervention: Screening-level FRAX score
Number of subjects: 6096
Study: 28285236

Group type: EXPERIMENTAL
Intervention: NEPA+DEX
Number of subjects: 1460

Group type: COMPARATOR
Intervention: oral PALO+DEX
Number of subjects: 1460
Study: 28285240

Group type: EXPERIMENTAL
Intervention: Conventional therapy associated with SKY (Treatment)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 46
Study: 28285311

Group type: EXPERIMENTAL
Intervention: Wearable sensor monitoring of spontaneous daily physical activity (PAMSys™, BioSensics LLC)
Number of subjects: 120
Study: 28286093

Group type: EXPERIMENTAL
Intervention: EUS-guided needle-based confocal laser endomicroscopy (nCLE) for diagnosing mucinous PCLs
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: EUS-guided needle-based confocal laser endomicroscopy (nCLE) for diagnosing serous cystadenomas (SCAs)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Interobserver agreement (IOA) for nCLE image patterns
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability (IOR) for nCLE image patterns
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Interobserver agreement (IOA) for recognizing SCA image pattern
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intraobserver reliability (IOR) for recognizing SCA image pattern
Number of subjects: 29
Study: 28286192

Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 70
Study: 28286536

Group type: EXPERIMENTAL
Intervention: Serum ucOC
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Serum tOC
Number of subjects: 318
Study: 28286803

Group type: EXPERIMENTAL
Intervention: D2C7-(scdsFv)-PE38KDEL (D2C7-IT) immunotoxin therapy
Number of subjects: 0
Study: 28286967

Group type: EXPERIMENTAL
Intervention: GLP-1 agents
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 28287157

Group type: EXPERIMENTAL
Intervention: Local heating (LH)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Current induced vasodilation (CIV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Post-occlusive hyperemia (PORH)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Acetylcholine (ACh)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 17
Study: 28288572

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with modified FOLFIRI (mFOLFIRI)
Number of subjects: 61
Study: 28288655

Group type: EXPERIMENTAL
Intervention: Automated notification system for deteriorating ward patients (after intervention)
Number of subjects: 4402

Group type: COMPARATOR
Intervention: Control group (before intervention)
Number of subjects: 4402
Study: 28288678

Group type: EXPERIMENTAL
Intervention: Care Coordination Intervention (CCI) consisting of a tablet-based mobile platform, interagency communication protocol, and training protocol.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Care Coordination Intervention (CCI)
Number of subjects: 60